Table 1 Clinical findings on days 1–28 after EBOV challenge

From: Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb

Animal ID

Findings

Status

A1

---

Survived

A2

---

Survived

A3

Leukocytopenia (7, 21 and 28dpi)

Survived

A4*

Moderate rash (7dpi), Thrombocytosis (7 dpi)

Died - 7 dpi

A5

---

Survived

A6

Moderate rash (7dpi), Leukocytopenia (7 dpi), Thrombocytopenia (7 dpi), ALT↑↑↑ (7 dpi), AMY↓↓ (7 dpi), CRE↑ (7 dpi)

Died - 8 dpi

B1

Fever(5 dpi), Severe rash (5 dpi), Thrombocytopenia (5 dpi), ALP↑↑↑ (5 dpi), TBIL↑ (5 dpi), AMY↓(5 dpi), PHOS↑(5 dpi)

Died - 5 dpi

B2

Severe rash (7 dpi), Leukocytopenia (7dpi), Thrombocytopenia (7 dpi), ALP↑↑↑ (7 dpi), ALT↑ (7 dpi), BUN↑ (7 dpi), CRE↑ (7 dpi),

Died - 7dpi

  1. Hypothermia was defined as below 35°C. Fever was defined as ≥1.0°C higher than baseline. Mild rash was defined as focal areas of petechiae covering <10% of the skin, moderate rash as areas of petechiae covering 10 to 40% of the skin and severe rash as areas of petechiae and/or ecchymosis covering >40% of the skin. Leukocytopenia and thrombocytopenia were defined as a >30% decrease in numbers of white blood cells (WBCs) and platelets, respectively. Leukocytosis and thrombocytosis were defined as a twofold or greater increase in numbers of WBCs and platelets over baseline, where WBC count >11.000. ↑, two- to threefold increase, ↑↑, four- to fivefold increase, ↑↑↑, greater than fivefold increase. ↓, two- to threefold decrease, ↓↓, four- to fivefold decrease, ↓↓↓, greater than fivefold decrease. ALP, alkaline phosphatase, ALT, alanine aminotransferase, AMY, amylase, TBIL, total bilirubin, BUN, blood urea nitrogen, PHOS, phosphate, CRE, creatinine, ---, no change.
  2. *No serum biochemistry data for this animal.
Back to article page